Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies  by Kang, Sang-Moo et al.
www.elsevier.com/locate/yviroVirology 331 (2Modified HIV envelope proteins with enhanced binding to
neutralizing monoclonal antibodies
Sang-Moo Kang*, Fu Shi Quan, Chunzi Huang, Lizheng Guo1, Ling Ye,
Chinglai Yang, Richard W. Compans
Department of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Road, RRC 3086, Atlanta, GA 30322, United StatesAbstract
The target for neutralizing antibodies against human immunodeficiency virus (HIV) is the trimeric Env protein on the native virion.
Conserved neutralizing epitopes of receptor binding sites are located in the recessed core of the Env protein, partially masked by
glycosylations and variable loops. In this study, we have investigated the effects of modifications of the HIV Env protein by glycosylation
site mutations, deletions of variable loops, or combinations of both types of mutations on their protein functions and reactivities with
neutralizing antibodies. Modified Env proteins were expressed in insect or mammalian cells, and their reactivity with epitope-specific broadly
neutralizing monoclonal antibodies (Mabs) was determined by flow cytometry. A unique mutant designated 3G with mutations in three
glycosylation motifs within the V3/C3 domains surrounding the CD4 binding site showed higher levels of binding to most broadly
neutralizing Mabs (b12 and 2F5) in both insect and mammalian expression systems. Mutants with a deletion of both V1 and V2 loop domains
or with a unique combination of both types of mutations also bound to most neutralizing Mabs at higher levels compared to the wild-type
control. Most mutants maintained the ability to bind CD4 and to induce syncytium formation at similar or higher levels as compared to that of
the wild-type Env protein, except for a mutant with a combination of variable loop deletions and deglycosylation mutations. Our study
suggests that modified HIV Env proteins with reduced glycosylation in domains surrounding the CD4 binding site or variable loop-deleted
mutants expose important neutralizing epitopes at higher levels than wild type and may provide novel vaccine immunogens.
D 2004 Elsevier Inc. All rights reserved.
Keywords: Human immunodeficiency virus (HIV); Modified envelope proteins; Enhanced antigenicityIntroduction
Although human immunodeficiency virus type 1 (HIV-1)
was identified as the etiologic agent of AIDS in humans
nearly two decades ago, an effective vaccine against the
virus has not been developed yet. Considering the high cost
and serious side effects of anti-retroviral therapy and
continued increase in new infections with the virus in
developing countries, there is a great demand for developing
a vaccine against the virus. The envelope glycoprotein (Env)0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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States.of HIV-1 is the only viral target for neutralizing antibodies.
The gp120 and gp41 glycoproteins are bound to each other
noncovalently and form oligomers on the cell surface and on
virions (Chan et al., 1997; Lu et al., 1995). Infection of
CD4+ lymphocytes is initiated by binding of gp120 to the
CD4 molecule on the cell surface, followed by binding of
the gp120–CD4 complex to CXCR4 or CCR5 chemokine
receptors (Wu et al., 1996).
It has been difficult to elicit neutralizing antibodies by
vaccination that are broadly reactive against many HIV-1
isolates. However, a small number of human monoclonal
antibodies (Mabs) with broad neutralizing activities against
primary strains have been isolated and characterized from
infected individuals, and have revealed several neutraliza-
tion epitopes on HIV-1 Env gp120–gp41. These Mabs
include b12 that recognizes an epitope overlapping the CD4005) 20–32
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2001) and 2F5 that binds to an epitope near the trans-
membrane (TM) domain of the gp41 glycoprotein (Parker et
al., 2001), indicating that gp41 is also a target for
neutralizing antibodies. Mab 2G12 recognizes an epitope
around the V3/C3/V4 domain of gp120 that is dependent on
the presence of N-linked glycans in this region (Scanlan et
al., 2002; Trkola et al., 1996). Another Mab 17b recognizes
a region close to the coreceptor binding site, which is better
exposed following CD4 binding (CD4i epitope) (Kwong et
al., 1998; Sullivan et al., 1998). Antibodies to V2 and V3
loops display mainly isolate or type-specific neutralizing
activities, which can be detected early in infection (Etemad-
Moghadam et al., 1998). The CD4bs antibodies are
relatively prevalent in patient sera (Moore and Ho, 1993),
whereas antibodies to CD4i or 2G12 epitopes are rare
(Poignard et al., 2001; Thali et al., 1993).
The elimination of potential N-linked glycosylation
sites located in the V1V2 loops or the deletion of the V1
or V2 loops from the HIV glycoprotein resulted in an
increased susceptibility of these mutant viruses to
neutralization by certain Mabs or by sera collected from
infected individuals (Cao et al., 1997; Ly and Stamatatos,
2000; Srivastava et al., 2003; Stamatatos et al., 1998a).
This change in viral neutralization indicates that such Env
modifications increase the number or exposure of
available neutralization epitopes within the oligomeric
viral Env protein. Thus, to elicit neutralizing antibodies
that have broad cross-reactivity against a large number ofFig. 1. The construction of genetically modified HIV 89.6 Env proteins. The symb
(aa 164–194) domains shown as lines indicate deletions and replacement with a
denoted by triangles. 3G denotes three glycosylation motif mutations of Asn to G
motif mutations of Asn to Gln at aa 623 and 635, and 1G at aa 635 in gp41 near the
strain.genetically diverse HIV-1 isolates, it is of interest to
design vaccine candidates in which the conserved regions
of gp120 are exposed.
Not much is known about antigenic properties after
modifications in glycosylation or variable loop deletions of
the HIV trimeric Env glycoprotein. Also, the effects of
combined mutation of variable loop deletions and N-linked
glycan motifs on exposing important neutralizing epitopes
and on their functions have not been studied yet. To
address these issues, we genetically engineered the HIV-1
primary isolate 89.6 Env protein and generated a series of
Env modifications including deletions in the V1/V2 loop
region and mutations at sites of N-linked glycans within the
V3/C3 and gp41 domains. We have investigated the
reactivities of modified HIV-1 Env proteins with potent
neutralizing Mabs as well as their CD4 binding and fusion
functions.Results
Construction of genetically modified HIV 89.6 Env proteins
and their expression
To study the effects of multiple mutations on Env
protein functions and exposure of neutralizing epitopes, a
series of glycosylation site mutations in gp120 and gp41
and variable loop deletions was generated as shown in
Fig. 1. Glycosylation site mutant 3G contained mutationsol C indicates the N-glycosylation motifs. The V1V2 (aa 128–194) and V2
3-amino acid linker (Gly–Ala–Gly). The glycosylation motifs mutated are
ln at aa 304, 341, and 363 in the V3/C3 domains. 2G denotes glycosylation
TM domain. Numbers indicate amino acid (aa) residues based on HIV 89.6
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domain of gp120. The 3G–2G mutant was made by
combining mutations of 3G and mutations of Asn to Gln
at aa 623 and 635 near the gp41 TM domain (designated
2G). These gp41 mutations were designed with the
expectation that they might expose the gp41 epitopes.
The variable loop mutants dV1V2 and dV2 contained
deletions of aa from 128 to 194 and from 164 to 194,
respectively, which were replaced with the 3 aa Gly–Ala–
Gly. Mutant 3G-dV1V2-1G was generated by combining
mutations 3G, dV2, and a mutation of Asn to Gln at an
aa 635 near the TM domain of gp41.
The recombinant baculovirus (rBV) expression system
has been used extensively to produce virus-like particles
(VLPs) including HIV (Deml et al., 1997; Kang et al., 1999;
Wagner et al., 1996, 1998), simian immunodeficiency virus
(Kang and Compans, 2003), chimeric simian HIV (SHIV)
(Guo et al., 2003), papillomavirus (Shi et al., 2001), and
rotavirus (Coste et al., 2000), and these studies demon-
strated that VLPs could elicit strong immune responses in
animal models. Thus, noninfectious VLPs containing high
quantities of oligomeric HIV Env proteins may represent
potential candidate immunogens for a vaccine and it is
important to study neutralizing epitope exposure of HIV
Env expressed by the rBV expression system. Nevertheless,
considering that there is a difference in posttranslational
modification of N-glycans between insect cells (high-
mannose-type oligosaccharides) and mammalian cells
(complex type oligosaccharides) (Lanford et al., 1989) and
that some neutralizing antibodies, for example, Mab 2G12,
depend on carbohydrates of gp120, we compared the wild
type (WT) and mutant HIV-1 89.6 Env glycoproteins
expressed by both rBV and recombinant vaccinia virus
(rVV) expression systems. Sf9 insect cells were infected
with a rBV expressing WT or mutant Env protein, radio-
labeled, and used for immunoprecipitation by monkey anti-
SHIV 89.6 sera (Fig. 2A). Env mutant proteins were
expressed mostly as uncleaved precursor forms and were
found at similar levels as the WT HIV Env protein in cell
lysates. Mutant proteins migrated faster than the WT protein
as expected from the mutations introduced. These results
indicate that the mutated glycosylation sites were actually
used in the WT protein and that the variable loops were
deleted as designed. For the analysis of expression in
mammalian cells, CV-1 cells were infected with a rVV
expressing the wild type or mutant Env protein (Fig. 2B).
Most mutants showed similar levels of whole-cell protein
expression compared to the WT protein except for the 3G-
dV1V2 mutant that showed slightly lower expression. The
release of surface HIV Env into the culture supernatant was
observed at higher levels in cells infected with the 3G, dV2,
and dV1V2 mutants, but was lower in 3G-2G, 3G-dV1V2,
and 3G-dV1V2-2G than in WT.
To determine the cell surface expression of WT and
mutant Env proteins, we applied a similar approach using
fluorescence-activated cell sorting (FACS) analysis as inprevious studies (Koch et al., 2003; Si et al., 2001; Wyatt et
al., 1995). Infected cells were stained with a human
polyclonal anti-serum and flow cytometry analysis was
performed. Positive cells were gated and florescence
intensity was compared (Fig. 2C). Even considering the
possible different reactivities with polyclonal antibodies
between WT and mutants, levels of HIV Env on cell surface
were found to be similar between WT and mutants without
significant differences in both rBV expression (Fig. 2D) and
rVV expression (Fig. 2E).
Syncytium formation and CD4 binding
The HIV 89.6 env gene is derived from a dual-tropic
R5X4 virus, and its expression on cells expressing CD4
and either CXCR4 or CCR5 results in syncytium
formation (Doranz et al., 1996). To determine if the
mutant HIV Env proteins maintain fusion activity leading
to syncytium formation, HeLa-CD4 cells infected with
rVVs expressing WT or mutant Env protein were
observed. Formation of multinucleated cells (syncytia)
was readily visible under phase-contrast microscopy (Fig.
3A). A summary of these results is shown in Fig. 3B.
Mutant 3G showed higher syncytium formation ability
resulting in an increase in size and number of syncytia
compared to WT, whereas mutant 3G-dV1V2 did not show
any visible syncytia formation. All other mutants retained
the ability to form syncytia at similar levels as WT. When
the proteins were expressed in HeLa cells not expressing
CD4, neither the mutants nor the WT Env showed
syncytium formation (data not shown).
To determine whether the observed difference in
syncytium formation ability is due to differences in ability
to bind CD4 molecules, CV-1 cells were infected with
rVVs expressing WT or mutant Env proteins, incubated
with various concentrations of soluble CD4 molecules, and
bound CD4 determined using flow cytometry analysis of
surface-stained cells with anti-CD4 antibody (Fig. 4). All
mutants retained the ability to bind CD4 at levels similar
to WT Env except a V2-loop-deleted mutant that showed
slightly higher levels of CD4 binding. When the relative
affinities of mutants to the CD4 molecule were compared
in terms of logarithmic slope from the binding curve, dV2
showed the highest affinity value, which is 25% higher
than WT (9.57 versus 7.67). All other mutants showed
similar affinity values. The WT and mutant HIV Env
proteins expressed in insect cells could also bind CD4 as
determined by flow cytometry analysis although lower
levels of CD4 binding were found compared to expression
in CV-1 cells (data not shown). The results obtained here
are consistent with previous studies that demonstrated that
similar levels of CD4 binding of variable loop deleted
(dV1, dV1V2, dV1V2V3) and various glycosylation site
mutants of HIV Env were observed (McCaffrey et al.,
2004; Stamatatos and Cheng-Mayer, 1998b; Wyatt et al.,
1995).
Fig. 2. Immunoprecipitation of wild type and mutant HIV Env proteins. (A) Recombinant baculovirus (rBV) expression system. Sf 9 insect cells were infected
with a rBV expressing the wild type or mutant HIV Env protein at a MOI of 10. At day 1 postinfection, cells were metabolically labeled and cell lysates
immunoprecipitated using antisera from a monkey infected with SHIV 89.6. Proteins were analyzed by SDS-PAGE. WT (wild-type HIV 89.6 Env protein), 3G,
3G + 2G, dV2, dV1V2, 3G-dV1V2, and 3G-dV1V2-2G have been explained in Fig. 1. (B) Recombinant vaccinia virus (rVV) expression system. HeLa cells
were infected with rVVs at a MOI of 2. Cells were metabolically labeled and culture supernatants harvested to determine the HIV Env proteins secreted into the
medium. Culture supernatants and cell lysates were immunoprecipitated using antisera from a monkey infected with SHIV 89.6. (C) Flow cytometry profile of
cell surface expression of WT and mutant Env stained with Mab b12. SIVG: Sf 9 cells infected with a rBVexpressing SIV Gag. WT: Sf 9 cells infected with a
rBV expressing HIV 89.6 Env. 3G: Sf 9 cells infected with a rBV expressing mutant 3G Env. Positive cells were gated and mean fluorescent intensity (MFI)
was compared. (D) Binding of a patient polyclonal anti-serum to the WT and mutant HIV Env proteins expressed in Sf 9 insect cells. Sf 9 insect cells were
infected with rBVat a MOI of 10 and were harvested after 1 day postinfection. Cells (1  105) were stained with 80 diluted neutralizing sera from an HIV-1-
positive patient and levels of antibody binding were determined by flow cytometry analysis. (E) Binding of a patient polyclonal anti-serum to the WT and
mutant HIV Env proteins expressed in mammalian cells using a rVV expression system. CV-1 cells were infected with a rVV at a MOI of 2, harvested after 1
day postinfection, stained with 80 diluted neutralizing sera from an HIV-1-positive patient, and levels of antibody binding were determined by flow cytometry
analysis.
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Fig. 3. Syncytium formation induced by HIV Env WT or mutant proteins. (A) Examples of syncytium formation. HeLa-CD4 cells infected with a rVV
expressing WT or mutant Env protein at a MOI of 0.5 were monitored for the formation of syncytia under a light microscope and photographed with a 20
objective. Arrows indicate syncytia. (B) The relative syncytium formation activity was evaluated by counting syncytia of multinuclear cells under a microscope
with a 10 objective. The numbers indicate an average from counts at five different fields (an area of 1 mm2) in a well. VV T7, cells infected with rVV
expressing bacteriophage T7 polymerase. WT, 3G, and 3G-dV1V2 are described in Fig. 1.
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glycoproteins
Previous studies indicated that binding of antibodies to
cell surface-expressed HIV-1 Env was more relevant to the
neutralizing potency than binding to the monomeric gp120
protein (Doranz et al., 1996; Roben et al., 1994; Si et al.,
2001; Stamatatos et al., 2000). To investigate whether
mutations in glycosylation sites or variable loop deletions or
combined mutations affect interactions of the HIV-1 Env
glycoproteins with antibodies, we applied FACS analysis in
comparing the binding efficiency of a panel of Mabs with
broad neutralizing activities. Since the levels of cell surface
expression were similar but not identical among different
mutants, only the positive populations compared to negative
control cells were gated to compensate for these differences
(Fig. 2C) in evaluating the geometric mean fluorescence
intensity (MFI).
For anti-CD4bs Mab b12 that is known to be the most
potent and broadly neutralizing monoclonal antibody,
mutants 3G, dV1V2, and 3G-dV2-1G expressed in insect
cells showed higher binding than the WT. This higher
binding level was more prominent using low concentrationsof b12 antibody (Fig. 5A). Binding of anti-V3 loop Mab
447-52D to mutants 3G, dV1V2, 3G-2G, and 3G-dV2 was
higher than that of WT (Fig. 5B). It is interesting to note that
a combination mutant 3G-dV2-1G showed the highest
binding to this 447-52D antibody, indicating a possibility
that glycosylation of the gp41 domain may affect exposure
of the V3 loop epitope in the gp120 domain. These results
indicate that mutants 3G, dV1V2, and 3G-dV2-1G
expressed on insect cells present V3 loop and CD4 binding
site epitopes better than the WT Env protein.
Mab 2G12, which recognizes a carbohydrate-dependent
epitope in the V3/C3/V4 regions of gp120, showed the
highest binding to the mutant dV1V2 and secondly to the
mutant dV2 Env expressed in insect cells (Fig. 5C). All
other mutants containing deglycosylations showed lower or
similar binding to Mab 2G12 as compared to WT. Mab
17b, which binds to an epitope with increased exposure
following CD4 binding (CD4i epitope), showed the high-
est binding to mutant dV1V2 and then secondly to the
mutants 3G-dV2-1G and 3G-dV2 (Fig. 5D). Mab 670-
30D, which is specific for the C5 region of gp120
(Nyambi et al., 2000; Zolla-Pazner et al., 1995), did not
show differences in binding among mutants and WT.
Fig. 4. Binding of soluble CD4 to wild type and mutant HIV Env proteins
expressed on cells. WT, 3G, 3G + 2G, dV2, dV1V2, 3G-dV1V2, and 3G-
dV1V2-2G are described in Fig. 1. CV-1 cells were harvested at 1 day
postinfection, incubated with soluble CD4 (0.01–8 Ag/ml), and stained with
rabbit antihuman CD4 serum and with FITC-conjugated anti-rabbit IgG
serum subsequently. A representative was shown from three independent
experiments.
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expose epitopes against 2G12 and 17b better than other
mutants.
The 2F5 epitope is relatively well conserved among HIV
strains in terms of its linear sequence (Coeffier et al., 2000;
Zwick et al., 2001). Most of the mutants containing a 3G
mutation (3G, 3G-dV2-1G, 3G-2G, 3G-dV2) showed higher
levels of binding to Mab 2F5 than WT (Fig. 5E). The
presence of a glycosylation mutation close to the 2F5
epitope (3G-dV2-1G) increased the binding of 2F5 antibody
at low concentrations compared to the Env without thatFig. 5. Binding of neutralizing antibodies to the WT and mutant HIV Env proteins
and were harvested 1 day postinfection. Cells (1  105 cells/40 Al) were stained
cytometry analysis. SIVG, cells infected with rBVexpressing SIV Gag protein. WT
in Fig. 1. (A) Anti-CD4 binding site (CD4bs) Mab, b12. (B) Anti-V3 loop mo
dependent Mab, 2G12. (D) Mab 2F5 recognizing a gp41 epitope near the TM do
control, positive cells were gated to evaluate the geometric MFI as indicated. Amutation (3G-dV2). The variable loop-deleted mutant
dV1V2 again showed the highest binding to 2F5 among
the other mutants including WT. Overall, among the
mutants expressed in insect cells, 3G and some other
mutants containing 3G showed higher binding affinities to
most antibodies tested except for 2G12, whereas dV1V2
showed higher binding to all antibodies tested including
2G12.
Since it is known that the glycosylation patterns of
proteins are different between insect and mammalian cells,
we also wanted to determine the binding of mutants
expressed on CV-1 cells using rVV expression. Anti-CD4bs
Mab b12 with potent neutralizing activity to many HIV
clinical isolates showed higher binding to the 3G mutant but
lower binding to most other mutants (3G-2G, dV1V2, 3G-
dV1V2, 3G-dV1V2-2G) at low concentrations (Fig. 6A).
The 3G mutant also showed the highest binding to F105
anti-CD4bs antibody (data not shown). At relatively high
concentrations of antibody, mutants dV2 and 3G-dV1V2
showed an increased binding to anti-V3 loop-specific Mab
447-52D (Fig. 6B). Enhanced binding of mutants 3G and
dV2 to Mab 17b was also observed only at a high
concentration of antibody (Fig. 6D).
For HIV-1 gp120 carbohydrate-dependent Mab 2G12, a
variable loop-deleted mutant dV2 resulted in higher
binding while all other mutants containing deglycosylationexpressed in Sf9 insect cells. Cells were infected with rBV at a MOI of 10
with an antibody and levels of antibody binding were determined by flow
, 3G, 3G + 2G, dV2, dV1V2, 3G-dV1V2, and 3G-dV1V2-2G are described
noclonal antibody (Mab) 447-52D. (C) Carbohydrate and conformation-
main. (E) CD4 induced epitope-specific Mab, 17b. Compared to a negative
representative was shown from three independent experiments.
Fig. 6. Binding of neutralizing antibodies to WT and mutant HIV Env proteins expressed in mammalian cells using a rVV expression system. CV-1 cells were
infected with a rVVat a MOI of 2 and were harvested after 1 day postinfection. WT, 3G, 3G + 2G, dV2, dV1V2, 3G-dV1V2, and 3G-dV1V2-2G are the same
as described earlier. VV T7: rVVexpressing T7 polymerase. Cells (1  105) were stained with the same antibodies as described in Fig. 5. A representative from
three independent experiments is shown.
S.-M. Kang et al. / Virology 331 (2005) 20–3226mutations showed lower binding compared to the WT Env
(Fig. 6C). In contrast, a deglycosylation mutant 3G
displayed increased binding to anti-gp41 Mab 2F5
compared to other mutants. Overall, a variable loop-
deleted mutant dV2 (or dV1V2 in insect cell expression)
and the deglycosylation mutant 3G or some mutants
containing a 3G mutation showed higher binding to most
Mabs, which was similar although not identical to the
pattern observed in mutants expressed in insect cells.
However, several mutations resulted in decreased binding
to most Mabs tested, indicating complex interactions
between variable loops and glycosylations in maintaining
the conformation of HIV Env.Discussion
Immunogens presenting the epitopes for neutralizing
antibodies in a way that mimics their structure on the native
HIV-1 Env glycoprotein may be able to induce a polyclonal
response that includes broadly reactive neutralizing anti-
bodies. As an approach to identify such an immunogen, we
generated a series of genetically modified HIV Env proteins,
expressed them in both insect and animal cells, character-
ized their functional properties, and monitored their
antigenic characteristics using broadly reactive neutralizing
Mabs.The most interesting mutant Env protein that we
identified is 3G, which has three deglycosylations at aa
304, 341, and 363. To locate these three N-glycan motifs in
a three-dimensional structure model of gp120, the structure
was plotted as shown in Fig. 7 by following the coordinates
of the HXBc2 strain gp120 crystal structure reported
previously (Kwong et al., 1998; Wyatt et al., 1998). Since
there are few amino acid deletions or insertions in variable
loops between HXBc2 and 89.6 strains, aa 304, 341, and
363 in 89.6 strain Env are equivalent to aa 301, 339, and
362 in the HXBc2 strain, respectively. Although there are
dramatic antigenic differences between primary and labo-
ratory-adapted HIV-1, the structure of gp120 cores from
these isolates was demonstrated to be remarkably similar
and sequence changes were mostly positioned on the surface
(Kwong et al., 2001). Glycan Asn304 located near the
coreceptor binding domain is very well conserved in
primary isolates (95%). Also, this site is known to play a
role in modulating coreceptor usage and in resisting
neutralization by antibodies (Malenbaum et al., 2000,
2001; Polzer et al., 2002). Asn341, which is located in the
helix of the outer domain following the V3 loop, is
relatively well preserved in HIV-1 isolates (approximately
75%), and mutation of Asn341 to Gln resulted in an increase
for binding to the neutralizing b12 Mab (Scanlan et al.,
2002). As shown in Fig. 7, Asn363 is located in the middle
of the C3 domain near the critical residues for CD4 binding
Fig. 7. Location of three Asn aa (mutant 3G) in the three-dimensional
structure by plotting in the structure of the HIV-1 HXBc2 gp120 core
(Kwong et al., 1998). The structure was visualized using the RasMol view
program (www.umass.edu/microbio/rasmol/getras.htm). Three Asn residues
at 301, 339, and 362 equivalent to aa 304, 341, and 363 in 89.6 strain Env
protein are shown in red in the structure. The critical amino acids involved
in binding CD4 and coreceptor are shown in green and yellow, respectively.
The stems of the missing variable loops V1/V2 and V3 are indicated.
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Env has an N-glycan motif at this position. The 3G mutant
retained the normal level of precursor processing, cell
surface expression and CD4 binding, and exhibited signifi-
cantly enhanced syncytia forming activity. Importantly, this
mutant showed higher binding to the most broadly
neutralizing Mabs b12, 17b, and 2F5, indicating that
neutralizing epitopes may be more highly exposed in this
Env structure. Consistent with our results, Koch et al.
(2003) recently reported that primary isolate mutants
lacking the N-glycan at aa 301 in the V3 loop became to
be more sensitive to neutralization by CD4bs and V3 loop-
directed antibodies, and that additional mutations of N-
glycan motifs proximal to receptor binding regions rendered
these mutants sensitive to CD4i antibodies. These antigenic
changes might be beneficial in inducing broadly neutraliz-
ing antibodies since cross-neutralization by sera from
infected individuals is principally attributed to antibodies
against the conserved epitopes (Moore and Ho, 1993;
VanCott et al., 1995; Zhang et al., 1999).
Unexpectedly, combination mutations of variable loop
deletions and deglycosylations resulted in less efficient
binding to most neutralizing Mabs. An interesting result was
observed in syncytia-forming functions of these mutant
proteins. The deglycosylation mutant 3G showed thehighest syncytium formation activity while variable loop
deletion mutant dV1V2 retained a similar level of syncy-
tium formation as WT. However, the combined mutant 3G-
dV1V2 did not show any detectable syncytium formation.
The defect of the 3G-dV1V2 mutant in inducing syncytium
formation was not due to the inability to bind to CD4, since
this mutant showed a similar level of CD4 binding as the
WT Env. Interestingly, further deglycosylation of gp41 in
mutant 3G-dV1V2-2G restored the syncytium formation to
the level of WT. Thus, variable loops and carbohydrates
may interact interdependently in maintaining protein func-
tion and antigenic properties. Deglycosylations in the gp41
domain (mutants containing 1G or 2G) did not affect CD4
binding or syncytia-forming functions, which is expected
from a previous report that mutations of these glycosylation
sites were dispensable for viral replication in various cells
(Johnson et al., 2001). A unique combination mutant 3G-
dV2-1G highly increased the binding of Mabs b12, 447-
52D, and 2F5 compared to the counterpart mutant 3G-dV2.
These results indicate that glycans in gp41 play a role in
gp120 and gp41 interactions or modulating the antigenicity
of both gp41 and gp120.
The effect of variable-loop deletions on exposing
important neutralizing epitopes is not well understood yet.
Variable loop-deleted Env mutants expressed in mammalian
cells did not show a significant increase in binding to most
Mabs compared to the wild-type Env although the dV2
mutant showed a slight increase in binding to the V3 loop-
specific 447-52D, carbohydrate-dependent 2G12, and
CD4i-epitope recognizing 17b Mabs at relatively high
concentrations of antibody. Our results are consistent with
studies of a V2 loop-deleted mutant HIV SF162 Env
expressed in oligomeric gp140 form that showed higher
exposure of the V3 loop epitope but not CD4bs epitope
(Stamatatos et al., 2000). HIV-1 Env mutants lacking the V1
and V2 loops exhibited increased sensitivity to neutraliza-
tion by antibodies directed against the V3 loop and a CD4-
induced epitope on gp120, and by sera collected from
patients infected with different clades of HIV-1 primary
isolates (Cao et al., 1997; Stamatatos and Cheng-Mayer,
1998b). Serum from a monkey immunized with a V2 loop-
deleted immunogen was shown to have higher levels of
antibodies capable of neutralizing heterologous HIV-1
isolates than the parental strain SF162 (Barnett et al.,
2001). However, only selected heterologous isolates were
susceptible to neutralization by this serum and titers were
lower than those against the homologous SF162 strain. The
same group also reported that the V2 loop deletion did not
increase the immunogenicity of the CD4bs even though it
altered the immunogenicity of the V3 loop and C5 domain
(Srivastava et al., 2003). Also, by immunizing with rVV
expressing a V1–V2 loop-deleted HIV-1 gp160 and boost-
ing with the same mutant protein, higher neutralizing
activity was not achieved (Kim et al., 2003). Our study
and others therefore suggest that simply deleting the
variable loops may not expose conserved neutralizing
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Env protein.
The antigenicity of HIV Env proteins expressed in the
rBV expression system has not been studied well although it
may be an attractive system to produce a vaccine candidate
(Deml et al., 1997; Guo et al., 2003; Kang and Compans,
2003; Kang et al., 1999; Wagner et al., 1996, 1998). In
contrast to mammalian cells, significantly enhanced binding
to all neutralizing Mabs tested was observed in the V1–V2
variable loop-deleted mutant (dV1V2) expressed in insect
cells. This may be due to differences in posttranslational
modification between insect and animal cells. It has been
shown that the proteolytic processing of HIV Env is not
efficient in the baculovirus virus expression system (Hu et
al., 1987). Our results show that, in insect cells, mutant and
WT HIV Env proteins were expressed predominantly in the
unprocessed gp160 form. However, inefficient processing
does not imply that such Env proteins cannot be good
vaccine candidates. SF162 Env with V2 loop deletion when
expressed in a cleavage-defective oligomeric gp140 showed
higher binding to antibodies against the CD4bs (b12) or V3
epitopes (391-95D) (Stamatatos et al., 2000). It was also
shown that elimination of the cleavage site did not affect the
ability of a mutant protein to elicit neutralizing antibodies
(Srivastava et al., 2003). Another difference is that N-
glycans in insect cells are high-mannose-type oligosacchar-
ides compared to the complex-type oligosaccharides usually
produced in mammalian cells (Lanford et al., 1989).
Reflecting this difference, greater differences in binding to
carbohydrate-dependent Mab 2G12 were observed in Env
proteins expressed in insect cells.
To our knowledge, this is the first report investigating the
antigenicity of HIV Env mutants expressed in insect cells
and the effects of combined Env mutations. Based on the
results, several mutants (3G, dV1V2, 3G-dV1V2-1G)
produced in the baculovirus expression system may be
good candidates to evaluate the effect of deglycosylation or
variable loop deletions on inducing broadly neutralizing
antibodies. We are currently comparing the immunogenicity
of WT and mutant Envs to address some of these questions.
These ongoing studies will provide valuable information on
designing AIDS vaccine candidate antigens inducing
neutralizing antibodies.Materials and methods
Cells, viruses, and antibodies
Spodoptera frugiperda Sf 9 cells were maintained in
serum-free SF900 II medium (GIBCO-BRL) in spinner
flasks at a speed of 70–80 rpm. Baculovirus titers were
determined by a plaque assay following the manufacturer’s
protocol (BD PharMingen). A baculovirus-expressing SIV
Gag was previously described (Yamshchikov et al., 1995).
CV-1, HeLa, and HeLa T4 cells were maintained inDulbecco’s modified minimal essential medium (DMEM)
supplemented with 10% fetal calf serum (HyClone Labo-
ratories). The recombinant vaccinia virus (rVV) vTF7-3 and
monkey anti-SHIV 89.6 sera were kindly provided by Drs.
Bernard Moss (NIH) and Patricia Fultz (University of
Alabama at Birmingham), respectively. All antibodies used
in this study for flow cytometry analysis, soluble human
CD4 (cat #7356), and rabbit antihuman CD4 serum (cat
#806) were obtained from the NIH AIDS Research and
Reference Reagent Program. HIV-1 neutralizing serum (cat
#1984) neutralizes several HIV-1 strains, including IIIB/
LAV, RF, MN, and SF2. Anti-V3 loop monoclonal antibody
(Mab) 447-52D (cat #4030) neutralizes laboratory strains
that contain the GPGR sequence at the apex of the V3 loop
(Gorny et al., 1992). Anti-CD4 binding site (CD4bs) Mab
b12 (cat #2640) is a potent antibody that neutralizes diverse
primary HIV-1 isolates (Burton et al., 1991). Anti-CD4bs
Mab F105 (cat #857) reacts with a discontinuous gp120
epitope and neutralizes SF2, IIIB, and MN strains of HIV-1
(Posner et al., 1993). Carbohydrate and conformation-
dependent Mab 2G12 (cat #1476) neutralizes laboratory
HIV-1 strains IIIB, RF, and a broad variety of primary
isolates (Buchacher et al., 1994). CD4-induced epitope-
specific Mab 17b (cat #4091) has neutralizing activity
against several laboratory strains of HIV-1 and some
primary isolates (Sullivan et al., 1998). A gp41 epitope-
specific Mab 2F5 (cat #1475) neutralizes a broad variety of
laboratory HIV-1 strains and primary isolates (Purtscher et
al., 1996).
Plasmid construction
We used a rBV transfer vector pc/pS1-89.6 encoding the
HIV 89.6 Env protein with the cytoplasmic tail truncated to
17 amino acids (aa), allowing better cell surface expression
compared with the full-length Env glycoprotein (Yao et al.,
2000). For site-directed mutagenesis, the Env encoding gene
from pc/pS1-89.6 was subcloned to a small shuttle vector
pGEM (Promega) that is easy to manipulate and the cloned
plasmid designated pGEM-89.6. For mutations eliminating
glycosylation sites, we applied a QuickChange site-directed
mutagenesis kit (Stratagene) using the high fidelity poly-
merase with a proofreading activity. The paired mutagenic
PCR primers (Sigma Genosys) containing the Gln codon
CAG at the Asn position to be mutated were designed to be
complementary to each other. The primer pairs are as
follows and the numbers indicate the position being mutated
to Gln based on HIV 89.6 Env. F-304, 5V ACA AGA CCC
AAC CAG AAT ACA AGA AGA AGG 3V; R-304, 5V CCT
TCT TCT TGT ATT CTG GTT GGG TCT TGT 3V; F-341,
5V-AGT AGA GCA AAATGG CAG AAC ACT TTA CAA
CAG-3V; R-341, 5V-CTG TTG TAA AGT GTT CTG CCA
TTT TGC TCT ACT-3V; F-363, 5VAAA ACA ATA GCC
TTT CAG CAATCC TCA GGA GG-3V; R-363, 5V-CC TCC
TGA GGATTG CTG AAA GGC TAT TGT TTT-3V; F-623,
5V GATGAT ATT TGG AAT CAG ATG ACC TGG ATG
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CCA AAT ATC ATC 3V; F-635, 5V GG GAA AGA GAA
ATT GAC CAG TAC ACA GAC TAT A 3V; R-635, 5V-T
ATA GTC TGT GTA CTG GTC AAT TTC TCT TTC CC
3V. The thermocycle was 95 8C for 50 s, 55 8C for 1 min 20
s, and 68 8C for 10 min. The PCR product was treated with
DpnI (Stratagene) to digest a methylated template DNA.
The DpnI-treated PCR product was transformed into
competent Escherichia coli bacteria DH5a and the intended
mutated region of pGEM plasmids was confirmed by DNA
sequencing (Emory University Sequencing Facility). For
multiple mutations (3G or 3G-2G in Fig. 1), additional
mutations were introduced sequentially using the mutated
pGEM-89.6 as a template.
The technique of overlap PCR extension was applied for
generating variable loop deletion mutations (Ho et al.,
1989). For V1–V2 loop deletion of aa 128–194, two PCRs
were performed to amplify two coding sequences covering
aa 1–128 and the remaining part of the gene covering aa 194
to the C-terminal end. The deleted domain was replaced
with a linker of three amino acids, Gly–Ala–Gly between aa
128 and 194. N-terminus PCR primer set; F1:
GGTACCCGGGCAGAAGACAG (underline denotes SmaI
recognition site) and R-V1V2: CCT TCC TGC TCC AAC
ACA GAG TGG GGT TAA TTT T (bold type denotes
codons for the 3-amino acid linker and contains the
overlapping nucleotides with the C-terminus product). C-
terminus PCR primer set: R1: TCGACTCTAGACCCCTC-
GATCA (underline denotes XbaI recognition site) and F2-
V1V2, GGAGCAGGAAGGTTAATAAGTTGTAACAC
(bold type denotes codons of the 3-amino acid linker and
contains the overlapping nucleotides with the N-terminus
product). After PCR reactions, two PCR products were
isolated separately, purified, and linked together via the 2nd
round PCR with F1 and R1 primers. This PCR product was
cloned into the pGEM plasmid after digestion with SmaI
and XbaI restriction enzymes. For V2 loop deletion of aa
164–194, a similar protocol was applied using the following
primers; F-dV2: 5V GGA GCC GGG AGG TTA ATA AGT
TGT AAC ACC TCA GTC-3V, R-dV2: 5V GAT ATA GAA
AGA GCA ATT TTT TAT TTC 3V. All mutant pGEM
plasmids were sequenced to confirm that the desired
mutations were obtained. For combined mutations contain-
ing variable loop deletions and deglycosylations, site-
directed mutagenesis of glycosylation sites was performed
using the variable loop-deleted pGEM mutant plasmid
(dV1V2 or dV2 in Fig. 1) as a template DNA.
Generation of recombinant baculoviruses (rBV) and
vaccinia viruses (rVV)
The confirmed mutant HIV env genes (in pGEM vector)
as described above were cloned into the baculovirus transfer
vector pc/pS1 for the construction of rBVs. To obtain rBVs
expressing mutant HIV Env proteins, Sf 9 insect cells were
cotransfected with linearized AcNPV Baculogold DNA (BDPharMingen) and a pc/pS1 transfer vector containing the
mutated HIV env gene following the manufacturer’s
procedure. Five days after co-transfection, the media
containing recombinant viruses were collected by centrifu-
gation at 1500  g for 20 min. Since Baculogold DNA
generates greater than 99% pure recombinant virus pop-
ulation (BD PharMingen), the recombinant virus in the
culture supernatant was further propagated and a plaque
assay performed and used for protein expression.
For construction of rVVs expressing mutant HIV Env
protein, the confirmed mutant HIV env genes from pGEM
DNAs were cloned into the plasmid pRB21 with a strong
synthetic VV early/late promoter (Blasco and Moss, 1995)
using EcoRI and HindIII restriction enzymes. CV-1 cells
infected with a mutant nonplaque-forming VV vRB12 were
transfected with a pRB21 plasmid containing a mutant or
wild-type HIV env gene using Lipofectin transfection
reagent (Invitrogen) following the manufacturer’s proce-
dure. Recombinant VVs were identified by their ability to
form plaques and single plaques were purified for three
rounds following a standard protocol (Blasco and Moss,
1995). The rVV stocks were propagated on CV-1 cells and
their titers determined and used for protein expression.
Protein expression
Expression of modified HIV Env proteins was confirmed
by metabolic labeling of infected Sf9 insect cells or HeLa
cells and immunoprecipitation with a monkey anti-SHIV
89.6 sera. Sf9 cells were infected with an rBV containing
wild type or mutant HIV env gene at a multiplicity of
infection (MOI) of 10. The cells were starved with SF900 II
methionine and cysteine-deficient medium (GIBCO-BRL)
at 24 h postinfection for 30 min, and labeled with 100 AC of
[35S]methionine and [35S]cysteine mix/ml for 1 h at 27 8C.
Cells were lysed in a radioimmunoprecipitation assay
(RIPA) buffer (150 mM NaCl, 50 mM Tris–HCl [pH 7.5],
1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1
mM EDTA, protease inhibitor cocktail tablet (Roche
Molecular Biochemicals) for 10 min on ice. The cell lysate
was immunoprecipitated with monkey anti-SHIV sera at 4
8C for 2 h and protein A overnight. The precipitate was
washed three times in RIPA buffer and analyzed by SDS-
polyacrylamide gel electrophoresis (PAGE) and subse-
quently by autoradiography. For rVV expression, HeLa
cells (1  106 cells) were infected with rVV at MOI of 1.
Cells were starved with DMEM with Met and Cys for 30
min at 16 h postinfection. Cells were labeled as above and
lysed in 50 mM Tris–HCl pH 7.5, 1 mM EDTA, 1% Triton
X-100, 1% Na-deoxycholate, 150 mM NaCl. The cell
lysates were immunoprecipitated and analyzed as above.
Antibody binding analysis by flow cytometry
Measurement of antibody binding to Sf 9 or CV-1 cells
expressing modified HIV-1 Env proteins was performed by
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ing a similar procedure as described (Koch et al., 2003; Si et
al., 2001, 2003; Wyatt et al., 1995; Zolla-Pazner et al., 1995).
Sf 9 insect cells were infected with a rBV (MOI = 10)
expressing SIV Gag (SIVG) as a negative control, wild type
(WT), or mutant Env protein and cultured in suspension.
After 1 day postinfection, cells were harvested. Sf9 cells (1
105) were stained in 40 Al of staining buffer (phosphate-
buffered saline (PBS), 2% bovine serum albumin). The
concentrations of Mabs used for staining 1  105 cells were
0.04–2 Ag/ml of 447-52D, 0.04–10 Ag/ml of b12, 0.2–5 Ag/
ml of F105, 0.08–12 Ag/ml of 2G12, 0.08–12 Ag/ml of 17b,
and 0.16–4 Ag/ml of 2F5. Neutralizing serum was diluted 40-
to 80-fold. After 1 h of incubation at room temperature (RT),
cells were washed twice with 200 Al of staining buffer and
resuspended in 40 Al of staining buffer containing a 1:200
dilution of phycoerythrin-conjugated goat antihuman anti-
body (Southern Biotech). The binding reaction mixtures were
incubated at RT for another 1 h. Cells were washed two times
with staining buffer, suspended in 200 Al of 0.5% parafor-
maldehyde in PBS buffer, and analyzed with a FACS Calibur
instrument (Becton Dickinson) and WINMDI 2.8 software
(Scripps Research Institute Cytometry Software). Comparing
to a negative control, only positive cells were gated to
evaluate the geometric mean fluorescence intensity (MFI)
(see Fig. 2C).
CV-1 cells were infected with rVVs (MOI = 2)
expressing wild type (WT) or mutant HIV Env protein or
vTF7-3 expressing T7 polymerase (VV T7) as a negative
control. At 18–20 h postinfection, CV-1 cells were detached
with 5 mM EDTA in PBS, washed in PBS, and suspended
in staining buffer. CV-1 cells (1  105) were stained with
antibodies and analyzed by FACS in the same way as
described above.
CD4 binding and syncytium formation assays
For CD4 binding assay, CV-1 cells grown on 96-well
plate (4  104 cells/well) were infected with a rVVat a MOI
of 2. At 18–20 h postinfection, cells were washed with PBS
and fixed with 0.05% glutaraldehyde in PBS at 4 8C for 1 h.
After washing with staining buffer, cells were incubated
with soluble human CD4 at concentrations of 0.01–8 Ag/ml
in staining buffer at RT for 1 h. The amounts of bound CD4
were determined using rabbit antihuman CD4 serum
(1:10000) followed by horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgG polyclonal antibody
(1:2000). HRP substrate ABTS [2,2V-azino-bis(3-ethylbenz-
thiazoline-sulfonic acid)] containing H2O2 (Sigma) was
used to develop color and OD405 was read by ELISA
reader (MTX Lab Systems). Alternatively, the CD4 binding
was also determined by FACS analysis. The infected CV-1
or Sf9 insect cells were harvested at 20 h postinfection, and
incubated serially with CD4, rabbit antihuman CD4 serum,
and FITC-conjugated goat anti-rabbit IgG (1:200) as
described above.In previous studies, the fusion activity of HIV Env has
been determined by analyzing the formation of syncytia
(Doranz et al., 1996; Raja et al., 2003; Wyatt et al., 1995).
HeLa-CD4 cells were infected with rVVs expressing wild
type or mutant Env protein at a MOI of 0.5. Between 16 and
20 h postinfection, the formation of syncytia was monitored
under a light microscope and photographed. Syncytia of
multinuclear cells were counted at five different fields in a
well and averaged to evaluate the syncytium forming ability.Acknowledgments
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